Biomarker may ID gestational diabetes risk

Share this article:
Biomarker may ID gestational diabetes risk
Biomarker may ID gestational diabetes risk

HealthDay News -- Glycosylated fibronectin may be able to identify first-trimester pregnant women who are at risk for developing gestational diabetes, researchers found.

Above a threshold of 120 mg/L, glycosylated fibronectin levels had a 63% positive predictive value, correctly identifying 57 of 90 pregnant women who developed diabetes at 5 to 13 weeks gestation (95% CI: 53%-72%) and a 95% negative predictive value (95% CI: 94%-95%), Juha P. Rasanen, MD, PhD, of Oregon Health and Science University in Portland, and colleagues reported in Obstetrics & Gynecology.

To evaluate whether certain biomarkers have the potential to identify pregnant women in the first trimester who are at risk for developing gestational diabetes later, the researchers compared serum concentrations of glycosylated fibronectin, adiponectin, sex hormone-binding globulin, placental lactogen and high sensitivity C-reactive protein among 90 pregnant women who developed diabetes at 5 to 13 weeks gestation and 92 control participants.

The researchers observed a significant association between gestational diabetes and  first-trimester serum concentrations for all of the potential biomarkers; however, glycosylated fibronectin was the only serum identified that remained independently associated with developing gestational diabetes after the researchers adjusted for maternal factors and other markers (P<.001).

"First-trimester glycosylated fibronectin is a potential pregnancy-specific biomarker for early identification of women at risk for gestational diabetes," the researchers wrote.

Several authors disclosed financial ties to DiabetOmics, which funded the study.


References

  1. Rasanen JP et al. Obstetrics & Gynecology. 2013; doi: 10.1097/AOG.0b013e3182a0c88b.
Share this article:
You must be a registered member of Clinical Advisor to post a comment.
close

Next Article in Web Exclusives

More in Web Exclusives

Fetal death, stillbirth up with higher maternal BMI

Fetal death, stillbirth up with higher maternal BMI

Overweight and obese women have an increased risk for poor birth outcomes compared with normal-weight women.

Fewer type 2 diabetes cases go undiagnosed

Fewer type 2 diabetes cases go undiagnosed

Prevalence higher and glycemic control poorer in non-Hispanic blacks and Mexican-Americans, but lower percentage of type 2 diabetes cases left undiagnosed overall.

Second oral tablet approved for grass allergies

Second oral tablet approved for grass allergies

Merck's Grastek becomes the second sublingual treatment for grass pollen-induced allergic rhinitis with or without conjunctivitis.